Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Brandi, Giovanni ^a,b   Tavolari, Simona ^a,b   De Rosa, Francesco ^a   Di Girolamo, Stefania ^a   Agostini, Valentina ^a   Barbera, Maria Aurelia ^a   Frega, Giorgio ^a   Biasco, Guido ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; GABEXATE MESILATE; K RAS PROTEIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B RAF KINASE GENE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; ONCOGENE K RAS; PIK3CA GENE; TUMOR GENE; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; CULTURE MEDIA, CONDITIONED; GABEXATE; HUMANS; MUTATION; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84864186951     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041347     Document Type: Article

References (26)

1. Van Cutsem E, Nordlinger B, Cervantes A, (2010) ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21: v93-97.
2. Meyerhardt JA, Mayer RJ, (2005) Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
5. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, et al. (2009) Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6: 519-527.
6. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096.
7. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of Cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
8. De Mattos-Arruda L, Dienstmann R, Tabernero J, (2011) Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer. Clin Colorectal Cancer 10: 279-289.
9. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, et al. (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851-1857.
10. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A, (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101: 1308-1324.
11. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S, (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12: 594-603.
12. Yoon WH, Jung YJ, Kim TD, Li G, Park BJ, et al. (2004) Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Clin Cancer Res 10: 4517-4526.
13. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, et al. (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961.
14. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, et al. (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130: 247-253.
15. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, et al. (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2: 135-164.
16. Prenen H, Tejpar S, Van Cutsem E, (2010) New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 16: 2921-2926.
17. Lee J, Lee I, Han B, Park JO, Jang J, et al. (2011) Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 103: 674-688.
18. Brandi G, Biasco G, Tavolari S, (2011) Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 103: 1278.
19. Seta T, Noguchi Y, Shimada T, Shikata S, Fukui T, (2004) Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol 16: 1287-1293.
20. Seta T, Noguchi Y, (2011) Protease inhibitors for preventing complications associated with ERCP: an update meta-analysis. Gastrointest Endosc 73: 700-706.
21. Takahashi H, Funahashi H, Sawai H, Matsuo Y, Yamamoto M, et al. (2007) Synthetic serine protease inhibitor, gabexate mesilate, prevents nuclear factor-kappaB activation and increases TNF-alpha-mediated apoptosis in human pancreatic cancer cells. Dig Dis Sci 52: 2646-2652.
22. Ozeki T, Natori T, (2010) The specific inhibition of HepG2 cells proliferation by apoptosis induced by gabexate mesilate. Int J Clin Exp Pathol 3: 710-717.
23. Ohta N, Yotsuyanagi T, Ikeda K, (1986) Degradation of gabexate mesilate catalyzed by human serum albumin. Int J Pharm 29: 137-146.
24. Albini A, Benelli R, (2007) The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nature Protocols 2: 504-511.
25. Barendsz-Janson AF, Griffioen AW, Muller AD, van Dam-Mieras MC, Hillen HF, (1998) In vitro tumor angiogenesis assays: plasminogen lysine binding site 1 inhibits in vitro tumor-induced angiogenesis. J Vasc Res 35: 109-114.
26. Soares R, Balogh G, Guo S, Gärtner F, Russo J, et al. (2004) Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol 18: 2333-2343.